Chimeric antigen receptor-modified T-cell therapy for bone marrow and skin relapse Philadelphia chromosome-like acute lymphoblastic leukemia
| Autor: | Jianxiang Wang, Min Wang, Yuntao Liu, Mianzeng Yang, Yingxi Xu, Yingchang Mi, B F Gong, Ying Wang, X Y Gong, Bingcheng Liu |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
Oncology medicine.medical_specialty Skin Neoplasms Adolescent Ph-like acute lymphoblastic leukemia medicine.medical_treatment Philadelphia chromosome Immunotherapy Adoptive 03 medical and health sciences 0302 clinical medicine chimeric antigen receptor-modified T-cell therapy Precursor B-Cell Lymphoblastic Leukemia-Lymphoma hemic and lymphatic diseases Internal medicine Humans Medicine Philadelphia Chromosome Clinical Case Report 030212 general & internal medicine relapse Chemotherapy medicine.diagnostic_test business.industry Bone Marrow Smear Remission Induction Hematopoietic Stem Cell Transplantation Leukemia cutis General Medicine medicine.disease Minimal residual disease Leukemia medicine.anatomical_structure 030220 oncology & carcinogenesis Skin biopsy Bone marrow Neoplasm Recurrence Local medicine.symptom Bone Marrow Neoplasms business Research Article |
| Zdroj: | Medicine |
| ISSN: | 1536-5964 0025-7974 |
| Popis: | Rationale: Chimeric antigen receptor-modified T-cell (CART) therapy has revolutionized the treatment of patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). However, the capacity of CART therapy has not yet been fully elucidated. Patient concerns: An 18-year-old Chinese male patient presented with multiple firm masses on the skin all over his body following regular chemotherapy. Diagnoses: Bone marrow smear and skin biopsy confirmed that it was a bone marrow and skin relapse from the initial B-cell ALL. Interventions: CD19 CART-cell therapy was performed to manage the bone marrow and skin of the relapsed B-cell ALL. Outcomes: During CART-cell therapy, cytokine release syndrome and central nervous encephalopathy occurred. Eventually, the lesions disappeared, and the bone marrow and skin tested minimal residual disease (MRD) negative. The patient achieved complete remission (CR). Fourteen days after testing MRD negative, he received allogeneic hematopoietic stem-cell transplantation and has remained disease free to date. Lessons: The CR of this patient with leukemia cutis demonstrated that CART exhibited efficacy in this case. While further research is still required, this treatment could potentially be used as a therapy for skin leukemia, lymphoma, and other primary skin cancers. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|